HUM Stock Price Today (October 2026) — Humana Inc. Analysis & Key Metrics 2026-10-20
Humana Inc. (HUM) is trading at $427.38, up 2.99% today (as of October 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $465.13 (8.8% upside).
- Volatility is high (49.74% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (26.20% YoY) alongside competitive pressures in the Healthcare Plans space.
HUM Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Humana Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $42.19B
P/E Ratio
Forward P/E: 23.13
Revenue Growth
Year over Year
Analyst Target
+8.8% upside potential
Key Investor Questions About HUM
What investors need to know before buying
Based on current market data, HUM presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 60.10)
- Fundamentals say: Looking solid (debt and growth supportive)
HUM's growth trajectory depends on its ability to expand within the Healthcare Plans sector while managing margin pressures.
- Future growth will depend on performance in core Healthcare Plans operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for HUM investors include debt exposure and competitive dynamics in the Healthcare Plans industry.
- $14.74B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Healthcare Plans.
52-Week Trading Range
Over the past year, HUM stock traded between $163.11 and $456.50 and currently trades near the high end of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 49.74% annualized volatility and β=0.57, the stock exhibits low sensitivity to market moves—making HUM suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Moderate ownership metrics suggest a balanced supply-demand dynamic.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
Dow Jones Futures Rise, AI Stocks Jump On SpaceX, Supermicro; Tesla, Meta On Deck
How CVS' Aetna Is Advancing Efforts to Reduce Administrative Burden
Older Americans brace for higher healthcare costs ahead of midterms
Management Raised The Bar For CVS Health Stock; Does The Chart Agree?
What Would It Take For Rising Medical Costs To Break UnitedHealth Stock?
Latest TickZen Insights
All insights →No TickZen article on HUM yet. Our newest analysis:
Explore More Analysis for HUM
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 6, 2026 (before the open)
Frequently Asked Questions
Common investor questions about Humana Inc.
Humana Inc. (HUM) is currently trading at $427.38. The RSI (14-day) is at 60.1, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $465.13 implies 8.8% upside from current levels. Volatility is high at 49.7% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Humana Inc. (HUM): The trailing P/E ratio is 38.76, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 23.13, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 2.22, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 2.54. Price-to-Sales is 0.34. Valuation should be compared to Healthcare Plans industry peers for context, as different sectors trade at different multiples.
Based on 24 analysts covering HUM, the consensus price target is $465.13. This represents a 8.8% upside from the current price of $427.38. The range spans from a low target of $280.00 to a high target of $596.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Humana Inc. (HUM) pays a dividend with a current yield of approximately 0.84%. The annualized dividend rate is $3.54 per share. The payout ratio is 33.5%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was Oct 30, 2026.
Key risks for Humana Inc. (HUM) investors include: 1. High volatility (49.7% annualized)—the stock can experience significant daily price swings. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Healthcare Plans sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Humana Inc.'s (HUM) current debt and financial health profile: Total debt stands at $14.74B. The debt-to-equity ratio is 0.76x, which is moderate and generally manageable for most companies. The current ratio is 1.74, indicating strong short-term liquidity. The quick ratio is 1.29. The company holds $23.87B in cash and equivalents. Free cash flow is positive at $1.94B, providing a cushion for debt servicing and shareholder returns.